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Osteoporosis is a costly condition1,2 and is the fifth 
most common musculoskeletal problem managed in 
general practice at 0.9 per 100 patient encounters.3 
Secondary prevention of osteoporotic fracture is poorly 
implemented4 despite the availability of efficacious 
treatments. 
	
Strontium	 ranelate,	 a	 pharmacological	 treatment	 for	
osteoporosis	which	 is	 relatively	new	 to	Australia,	has	been	
available	 on	 the	 Pharmaceutical	 Benefits	 Scheme	 (PBS)	
by	 authority	 prescription	 since	April	 2007.5	 Strontium	 is	
the	pharmacologically	 active	 component	of	 the	compound	
and	 has	 been	 shown	 to	 simultaneously	 decrease	 bone	
resorption	and	stimulate	bone	formation	both	in	vitro	and	in	
animal	models,6	 although	 the	exact	mechanisms	 for	 these	
actions	are	as	yet	unclear.	
	 O’Donnell	et	al1	performed	a	systematic	review	to	assess	
the	 efficacy	 and	 adverse	 effects	 of	 strontium	 compared	
to	either	placebo	or	other	 treatments	 for	 postmenopausal	
osteoporosis.	The	 review	 results	 are	 summarised	 in	Table 
1	 and	how	 these	 results	might	 affect	 practice	 are	 shown	
in	Table 2.
This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the findings of recent 
Cochrane musculoskeletal reviews in a context immediately relevant to general practitioners. This article considers 
whether the availability of strontium ranelate affects the management of postmenopausal osteoporosis.
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 CLINICAL 
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Cochrane reviews 
Table 1. Key review results1
•	 	The	review	included	four	randomised	controlled	trials	(RCTs)	three	of	which	were	termed	treatment	populations,	with	a	mean	
lumbar	spine	T-score	<–2.5.7–9	In	two	of	these,	all	participants	had	sustained	a	previous	vertebral	fracture,7,8	and	in	one,	around	
55%	had	sustained	either	vertebral	or	nonvertebral	fracture.9	The	fourth	study	was	in	early	postmenopausal	women	with	T-score		
<–2.5	and	no	fracture10	(termed	a	prevention	population)
•	 	All	participants	in	the	studies	in	treatment	populations	received	both	calcium	and	vitamin	D	supplementation
•	 	2	g	of	strontium	ranelate	given	daily	for	3	years	in	a	treatment	population1	resulted	in	a	37%	reduction	in	vertebral	fractures	(RR:	
0.63,	95%	CI:	0.56,	0.71)	and	a	14%	reduction	in	nonvertebral	fractures	(RR:	0.86,	95%	CI:	0.75,	0.98).	The	number	needed	to	treat	
(NNT)	to	prevent	one	vertebral	fracture	over	3	years	was	13,	and	to	prevent	one	nonvertebral	fracture,	58
•	 	The	NNT	to	prevent	one	vertebral	fracture	over	1	year	was	32
•	 	In	the	single	study9	measuring	hip	fracture	outcomes	separately,	after	3	years	there	was	a	15%	decrease	in	risk	of	hip	fracture	
which	was	not	statistically	significant	(RR:	0.85,	95%	CI:	0.61–1.19)	in	the	full	study	sample	(n=4932),	and	a	decrease	of	36%	(RR:	
0.64,	95%	CI:	0.41–0.99)	in	a	subgroup	(n=1977)	at	high	risk	of	hip	fracture	defined	by	age	>74	years	of	age	and	a	femoral	neck	
bone	mineral	density	(BMD)	T-score	<–3.	Hip	fracture	was	not	the	primary	outcome	for	this	study,	and	the	study	was	not	designed	
with	sufficient	power	to	examine	hip	fracture	separately.	Thus	strontium’s	effect	at	the	hip	remains	unclear	
•	 	There	were	no	fracture	outcomes	measured	in	the	prevention	population,	although	strontium	ranelate	at	a	lower	dose	(1	g/day)	
than	that	which	reduced	fracture	risk	increased	BMD,	adjusted	for	strontium	content	of	bone,	at	the	lumbar	spine	by	1.4%.	The	
increase	at	the	femoral	neck	was	2.5%	but	this	was	not	adjusted	for	strontium	content	of	bone
•	 	Strontium	ranelate	did	not	cause	gastritis,	back	pain	or	death,	but	six	out	of	100	women	taking	strontium	ranelate	experienced	
diarrhoea	compared	to	four	out	of	100	taking	placebo,	with	a	number	needed	to	harm	of	56
•	 	The	risk	of	vascular	system	disorders	including	venous	thromboembolism	(two	trials,	n=6669,	2.2	vs.	1.5%,	OR:	1.5,	95%	CI:	1.1–
2.1)	and	pulmonary	embolism	(two	trials,	n=6669,	0.8	vs.	0.4%,	OR:	1.7,	95%	CI:	1.0–3.1)	as	well	as	nervous	system	disorders	such	
as	headache	(3.9	vs.	2.9%),	seizures	(0.3	vs.	0.1%),	memory	loss	(2.4	vs.	1.9%)	and	disturbance	in	consciousness	(2.5	vs.	2.0%)	is	
slightly	increased	with	taking	2	g	of	strontium	ranelate	daily	over	3–4	years	
•	 	There	were	no	RCTs	identified	which	compared	strontium	ranelate	to	other	treatments	of	postmenopausal	osteoporosis
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Conclusion
Strontium	 ranelate	 has	 demonstrated	 efficacy	
for	 the	prevention	of	 vertebral	 and	nonvertebral	
osteoporotic	 fracture	 in	postmenopausal	women	
who	have	previously	 sustained	 an	osteoporotic	
fracture	or	have	a	BMD	–2.5,	although	its	effect	on	
hip	 fracture	 risk	 is	 less	certain.	 In	 the	absence	of	
head-to-head	RCTs	it	is	not	possible	to	comment	on	
the	relative	efficacy	of	strontium	compared	to	other	
treatments	 such	as	bisphosphonates,	 raloxifene	
and	parathyroid	hormone.	However,	 its	 efficacy	
and	safety	suggests	 that	 it	 could	be	considered	
a	 first	 line	 treatment	 for	 postmenopausal	
osteoporosis	 and	 may	 be	 particularly	 useful	
where	bisphosphonates	are	contraindicated	or	not	
tolerated.	There	 is	potential	 for	strontium	ranelate	
to	play	a	role	in	the	prevention	of	postmenopausal	
bone	loss	as	it	has	been	shown	to	increase	BMD	
in	 this	 population,10	 and	posthoc	 analyses	have	
shown	 decreased	 fracture	 risk	 in	 osteopenic	
postmenopausal	 women	 without	 fractures.14	
However,	more	data	are	 required	 to	confirm	this.	
Further	 research	 is	 also	 needed	 to	 determine	
whether	 the	 efficacy	 of	 strontium	 ranelate	 is	
affected	by	previous	bisphosphonate	use.
Conflict	of	interest:	GJ	sits	or	has	sat	on	advisory	
boards	for	MSD	(alendronate),	Roche	(ibandronate)	
and	Servier	(strontium).	These	companies	had	no	
input	into	the	writing	of	this	paper.	
References
1. O’Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. 
Strontium ranelate for preventing and treating postmeno-
pausal osteoporosis. Cochrane Database Syst Rev 2006;3:
CD005326.
2. The burden of brittle bones: costing osteoporosis in Australia. 
Canberra: Access Economics, 2001.
3. Britt H, Miller G, Charles J, et al. General practice activity 
in Australia 2005–06. General practice series no. 19. AIHW 
cat. no. GEP 19. Canberra: Australian Institute of Health and 
Welfare, 2007.
4. National Institute of Clinical Studies. Evidence Practice Gaps 
report Vol 2. Melbourne: NICS, 2005.
5. Schedule of Pharmaceutical Benefits. Canberra: Australian 
Government, Department of Health and Ageing, 2007.
6. Marie PJ. Strontium ranelate: a dual mode of action rebal-
ancing bone turnover in favour of bone formation. Curr Opin 
Rheumatol 2006;18(Suppl 1):S11–5.
7. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium 
ranelate: dose dependent effects in established postmeno-
pausal vertebral osteoporosis: a 2 year randomised placebo 
controlled trial. J Clin Endocrinol Metab 2002;87:2060–6.
8. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium 
ranelate on the risk of vertebral fracture in women with post-
menopausal osteoporosis. N Engl J Med 2004;350:459–68.
9. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium 
ranelate reduces the risk of nonvertebral fractures in 
postmenopausal women with osteoporosis: Treatment of 
Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol 
Metab 2005;90:2816–22.
10. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, 
Roux C. Prevention of early postmenopausal bone loss by 
strontium ranelate: the randomised, two year, double masked, 
dose ranging, placebo controlled PREVOS trial. Osteoporos Int 
2002;13:925–31.
11. Anonymous. Australian Medicines Handbook. South 
Australia: Australian Medicines Handbook Pty Ltd, 2006.
12. Krueger CD, West PM, Sargent M, Lodolce AE, Pickard 
AS. Bisphosphonate induced osteonecrosis of the jaw. Ann 
Pharmacother 2007;41:276–84.
13. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate 
reduces the risk of vertebral and nonvertebral fractures in 
women eighty years of age and older. J Bone Miner Res 
2006;21:1113–20.
14. Seeman E, et al. Strontium ranelate: the first anti-osteoporotic 
agent to reduce the risk of vertebral fracture in patients with 
lumbar osteopenia. Paper presented at 1Oth World Congress 
on Osteoporosis, 14–18 May 2004: Rio de Janeiro.
Table 2. Putting evidence into practice 
Case study 1
Mrs	Casey,	68	years	of	age,	has	been	generally	well	and	leads	an	active	lifestyle	
with	regular	bushwalking.	She	recently	sustained	a	Colles’	fracture	when	she	slipped	
on	a	frosty	path.	Both	you	and	Mrs	Casey	are	concerned	about	the	possibility	of	
osteoporosis.	A	dual	energy	X-ray	absorptiometry	(DEXA)	scan	showed	that	her	lumbar	
spine	T-score	was	in	the	osteoporotic	range	at	–2.8.	She	wants	to	discuss	her	treatment	
options	with	you.	
Mrs	Casey	has	no	contraindications	to	any	of	the	PBS	listed	treatments	for	osteoporosis.	
You	explain	that	bisphosphonates,	specifically	alendronate	and	risedronate,	are	
recommended	as	first	line	treatment	to	prevent	subsequent	osteoporotic	fracture	because	
of	the	strength	of	evidence	for	their	effectiveness	at	preventing	both	vertebral	and	
nonvertebral	fractures	in	this	situation.11	You	explain	that	an	added	advantage	is	that	they	
can	be	taken	once	per	week	which	reduces	the	gastrointestinal	side	effects	and	makes	
them	easier	to	take.	You	mention	that	there	are	other	treatments,	the	main	options	being:
•	 	strontium	ranelate,	which	is	a	relatively	new	drug	which	has	to	be	taken	daily.	While	
this	review	has	shown	its	effectiveness	at	reducing	vertebral	and	nonvertebral	
fractures,	there	have	been	no	head-to-head	studies	with	bisphosphonates,	so	you	
cannot	directly	compare	it	with	these	first	line	drugs.	However,	the	magnitude	
of	benefit	in	terms	of	fracture	reduction	is	similar.	While	it	has	been	studied	in	
approximately	10	000	women	for	up	to	5	years,	it	has	not	yet	been	widely	used,	thus,	
there	may	be	as	yet	unknown	side	effects	associated	with	its	use11	as	has	recently	
been	shown	for	bisphosphonates	and	osteonecrosis	of	the	jaw.12	Despite	this,	the	
evidence	suggests	this	should	also	be	considered	as	a	first	line	treatment
•	 	raloxifene,	but	this	only	decreases	the	risk	of	vertebral	fractures	not	other	fractures	
and	is	considered	a	second	line	treatment11
•	 	parathyroid	hormone	increases	bone	density	substantially	and	decreases	both	
vertebral	and	nonvertebral	fractures	substantially.	It	has	been	used	in	over	100	000	
women	worldwide.	However,	it	requires	daily	injections	under	the	skin,	is	not	listed	
on	the	PBS	and	costs	$16	000	per	18	month	course.	It	is	generally	used	for	severe	
osteoporosis	or	when	other	agents	are	unsuitable.11
You	recommend	the	use	of	a	bisphosphonate	to	start	with,	and	Mrs	Casey	is	happy	with	
this	recommendation.
Case study 2
Mrs	Yusef,	82	years	of	age,	has	been	discharged	from	hospital	after	a	fractured	neck	of	
femur.	In	hospital	she	was	commenced	on	alendronate	to	treat	her	osteoporosis	and	
prevent	further	fracture.	While	Mrs	Yusef	is	physically	reasonably	well,	you	are	aware	that	
there	are	some	issues	with	her	memory,	which	have	been	brought	to	your	attention	by	
her	husband.	Today	her	husband	comes	in	concerned	because	he	is	finding	it	increasingly	
difficult	to	ensure	that	his	wife	stays	upright	for	the	30	minutes	necessary	after	her	weekly	
dose	is	taken,	and	she	is	complaining	about	indigestion	after	taking	the	alendronate.		
What	do	you	do?
Mrs	Yusef’s	inability	to	stay	upright	for	the	30	minutes	necessary	after	drug	
administration	is	a	contraindication	to	her	use	of	oral	bisphosphonates.	Strontium	
ranelate	(2	g	of	granules	mixed	in	water)	is	taken	at	bed	time,	2	hours	after	food	with	no	
other	special	instructions	and	is	effective	at	reducing	both	vertebral	and	nonvertebral	
fractures.	You	decide	that	in	this	situation,	strontium	ranelate	is	the	simplest	alternative	
treatment	to	try	first,	especially	as	it	is	the	only	agent	which	has	been	shown	to	prevent	
fractures	in	those	over	80	years	of	age.13 CORRESPONDENCE email: afp@racgp.org.au
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